Immix Biopharma Inc
Research Immix Biopharma Inc (IMMX) on Bullrun: market cap USD 1.04B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMMX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.04B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 11.56M
- Free cash flow-USD 11.76M
Valuation Snapshot
latest market cap is USD 1.04B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 29.40M | -USD 24.66M | n/a | -0.89 | USD 93.93M | USD 1.07M | USD 93.80M |
| FY2024 | USD 0 | -USD 21.61M | -USD 15.77M | n/a | -0.76 | USD 17.68M | USD 1.07M | USD 13.25M |
| FY2023 | n/a | -USD 15.43M | -USD 11.42M | n/a | -0.89 | USD 17.51M | USD 0 | USD 16.41M |
| FY2022 | n/a | -USD 8.23M | n/a | n/a | -0.59 | USD 13.44M | n/a | USD 13.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.04B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 276.93M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 60.59M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 137.48M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 31.89M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 47.09M | n/a | n/a | n/a |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immix Biopharma Inc's market cap?
Immix Biopharma Inc's market capitalization is USD 1.04B.
What does Immix Biopharma Inc do?
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.